CYCLERION THERAPEUTICS, INC. Stock-Based Compensation
CYCLERION THERAPEUTICS, INC. (CYCN) reported Stock-Based Compensation of $109.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- CYCLERION THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $51.00K, a 55.26% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $58.00K, a 49.12% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $95.00K, a 22.13% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $118.00K, a 14.49% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $1.07M, a 82.93% decline from fiscal 2022.
- CYCLERION THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $6.25M, a 34.95% decline from fiscal 2021.
- CYCLERION THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2021 was $9.61M, a 35.89% decline from fiscal 2020.
- CYCLERION THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2020 was $14.99M, a 23.63% decline from fiscal 2019.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $51.00K derived: 10-Q 6 month − S-4/A 3 month · filed 2026-08-04 | $109.00K 10-Q · filed 2026-08-04 | $204.00K derived: sum of 3 quarters · filed 2026-08-04 | $322.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $58.00K S-4/A · filed 2026-07-22 | $153.00K derived: sum of 2 quarters · filed 2026-07-22 | $271.00K derived: sum of 3 quarters · filed 2026-07-22 | $385.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $95.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-07-22 | $213.00K derived: sum of 2 quarters · filed 2026-07-22 | $327.00K derived: sum of 3 quarters · filed 2026-08-04 | $441.00K S-4/A · filed 2026-07-22 |
| 2025-09-30 | $118.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $232.00K derived: sum of 2 quarters · filed 2026-08-04 | $346.00K 10-Q · filed 2025-11-12 | $468.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $114.00K derived: 10-Q 6 month − S-4/A 3 month · filed 2026-08-04 | $228.00K 10-Q · filed 2026-08-04 | $350.00K derived: sum of 3 quarters · filed 2026-08-04 | $488.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $114.00K S-4/A · filed 2026-07-22 | $236.00K derived: sum of 2 quarters · filed 2026-07-22 | $374.00K derived: sum of 3 quarters · filed 2026-07-22 | $558.00K derived: sum of 4 quarters · filed 2026-07-22 |
| 2024-12-31 | $122.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-07-22 | $260.00K derived: sum of 2 quarters · filed 2026-07-22 | $444.00K derived: sum of 3 quarters · filed 2026-07-22 | $625.00K S-4/A · filed 2026-07-22 |
| 2024-09-30 | $138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $322.00K derived: sum of 2 quarters · filed 2025-11-12 | $503.00K 10-Q · filed 2025-11-12 | $606.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $184.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $365.00K 10-Q · filed 2025-08-05 | $468.00K derived: sum of 3 quarters · filed 2025-11-12 | $627.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-03-31 | $181.00K 10-Q · filed 2025-05-06 | $284.00K derived: sum of 2 quarters · filed 2025-11-12 | $443.00K derived: sum of 3 quarters · filed 2025-11-12 | $822.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2023-12-31 | $103.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-12 | $262.00K derived: sum of 2 quarters · filed 2025-11-12 | $641.00K derived: sum of 3 quarters · filed 2025-11-12 | $1.07M 10-K/A · filed 2025-11-12 |
| 2023-09-30 | $159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $538.00K derived: sum of 2 quarters · filed 2024-11-14 | $964.00K 10-Q · filed 2024-11-14 | $2.09M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $379.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $805.00K 10-Q · filed 2024-08-07 | $1.93M derived: sum of 3 quarters · filed 2024-08-07 | $3.59M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $426.00K 10-Q · filed 2024-05-07 | $1.55M derived: sum of 2 quarters · filed 2024-05-07 | $3.21M derived: sum of 3 quarters · filed 2024-05-07 | $4.91M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $2.79M derived: sum of 2 quarters · filed 2024-03-05 | $4.49M derived: sum of 3 quarters · filed 2024-03-05 | $6.25M 10-K · filed 2024-03-05 |
| 2022-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $3.36M derived: sum of 2 quarters · filed 2023-11-13 | $5.13M 10-Q · filed 2023-11-13 | $7.67M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $3.47M 10-Q · filed 2023-07-28 | $6.01M derived: sum of 3 quarters · filed 2023-07-28 | $8.43M derived: sum of 4 quarters · filed 2023-07-28 |
| 2022-03-31 | $1.77M 10-Q · filed 2023-05-12 | $4.31M derived: sum of 2 quarters · filed 2023-05-12 | $6.73M derived: sum of 3 quarters · filed 2023-05-12 | $9.07M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $4.96M derived: sum of 2 quarters · filed 2023-03-22 | $7.30M derived: sum of 3 quarters · filed 2023-03-22 | $9.61M 10-K · filed 2023-03-22 |
| 2021-09-30 | $2.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $4.75M derived: sum of 2 quarters · filed 2022-11-03 | $7.06M 10-Q · filed 2022-11-03 | $10.27M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $2.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $4.65M 10-Q · filed 2022-08-09 | $7.86M derived: sum of 3 quarters · filed 2022-08-09 | $11.65M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $2.31M 10-Q · filed 2022-05-04 | $5.52M derived: sum of 2 quarters · filed 2022-05-04 | $9.31M derived: sum of 3 quarters · filed 2022-05-04 | $13.27M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $7.00M derived: sum of 2 quarters · filed 2022-02-24 | $10.96M derived: sum of 3 quarters · filed 2022-02-24 | $14.99M 10-K · filed 2022-02-24 |
| 2020-09-30 | $3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $7.75M derived: sum of 2 quarters · filed 2021-11-09 | $11.79M 10-Q · filed 2021-11-09 | $16.25M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $3.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $7.99M 10-Q · filed 2021-07-29 | $12.46M derived: sum of 3 quarters · filed 2021-07-29 | $17.41M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $4.04M 10-Q · filed 2021-04-30 | $8.51M derived: sum of 2 quarters · filed 2021-04-30 | $13.45M derived: sum of 3 quarters · filed 2021-04-30 | $19.68M derived: sum of 4 quarters · filed 2021-04-30 |
| 2019-12-31 | $4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $9.42M derived: sum of 2 quarters · filed 2021-02-25 | $15.64M derived: sum of 3 quarters · filed 2021-02-25 | $19.63M 10-K · filed 2021-02-25 |
| 2019-09-30 | $4.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $11.17M derived: sum of 2 quarters · filed 2020-11-05 | $15.16M 10-Q · filed 2020-11-05 | $18.77M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $6.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $10.21M 10-Q · filed 2020-08-03 | $13.82M derived: sum of 3 quarters · filed 2020-08-03 | $17.13M derived: sum of 4 quarters · filed 2020-08-03 |
| 2019-03-31 | $3.99M 10-Q · filed 2020-05-04 | $7.60M derived: sum of 2 quarters · filed 2020-05-04 | $10.91M derived: sum of 3 quarters · filed 2020-05-04 | $13.91M derived: sum of 4 quarters · filed 2020-05-04 |
| 2018-12-31 | $3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $6.92M derived: sum of 2 quarters · filed 2020-03-12 | $9.93M derived: sum of 3 quarters · filed 2020-03-12 | $12.43M 10-K · filed 2020-03-12 |
| 2018-09-30 | $3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $6.32M derived: sum of 2 quarters · filed 2019-11-12 | $8.82M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $5.51M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $2.51M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |